The endocannabinoid signaling system: A marriage of PUFA and musculoskeletal health

Journal of Nutritional Biochemistry

Volumn 21, Issue 12, 2010, Pages 1141-1152

  Watkins, Bruce A ^a,b,c   Hutchins, Heather ^a   Li, Yong ^a   Seifert, Mark F ^c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; CB1; CB2; Endocannabinoid signaling; Endocannabinoids; Human; Muscle; Omega 3 fatty acids; Polyunsaturated fatty acids; Rodent

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ARTICLE; BONE MASS; BONE METABOLISM; ENERGY METABOLISM; HUMAN; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE METABOLISM; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

RODENTIA;

EID: 78249246017     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.04.011     Document Type: Review

References (97)

1. Murray R.M., Morrison P.D., Henquet C., Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007, 8:885-895.
2. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
3. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
4. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005, 81:224-238.
5. Nogueiras R., Diaz-Arteaga A., Lockie S.H., Velasquez D.A., Tschop J., Lopez M., et al. The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 2009, 60:93-98.
6. Scherer T., Buettner C. The dysregulation of the endocannabinoid system in diabesity - a tricky problem. J Mol Med 2009, 87:663-668.
7. Beal J.E., Olson R., Lefkowitz L., Laubenstein L., Bellman P., Yangco B., et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997, 14:7-14.
8. Strasser F., Luftner D., Possinger K., Ernst G., Ruhstaller T., Meissner W., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006, 24:3394-3400.
9. Kirkham T.C. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009, 21:163-171.
10. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006, 91:3171-3180.
11. Bluher M., Engeli S., Kloting N., Berndt J., Fasshauer M., Batkai S., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053-3060.
12. Di Marzo V., Cote M., Matias I., Lemieux I., Arsenault B.J., Cartier A., et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009, 52:213-217.
13. De Kloet A.D., Woods S.C. Minireview: endocannabinoids and their receptors as targets for obesity therapy. Endocrinology 2009, 150:2531-2536.
14. Despres J.P. The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol 2007, 6:46-50.
15. Watt M.J. Adipose tissue-skeletal muscle crosstalk: are endocannabinoids an unwanted caller?. Diabetologia 2009, 52:571-573.
16. Gonthier M.P., Hoareau L., Festy F., Matias I., Valenti M., Bes-Houtmann S., et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 2007, 15:837-845.
17. Cote M., Matias I., Lemieux I., Petrosino S., Almeras N., Despres J.P., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007, 31:692-699.
18. Gasperi V., Fezza F., Pasquariello N., Bari M., Oddi S., Agro A.F., et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007, 64:219-229.
19. Di Marzo V., Ligresti A., Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond) 2009, 33(Suppl 2):S18-S24.
20. Osei-Hyiaman D., Depetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
21. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I., et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008, 118:3160-3169.
22. Murdolo G., Kempf K., Hammarstedt A., Herder C., Smith U., Jansson P.A. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 2007, 30:RC17-RC21.
23. Potenza M.V., Mechanick J.I. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr Clin Pract 2009, 24:560-577.
24. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovska A., Game P., Wittert G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007, 364:105-110.
25. Eckardt K., Sell H., Eckel J. Novel aspects of adipocyte-induced skeletal muscle insulin resistance. Arch Physiol Biochem 2008, 114:287-298.
26. Cavuoto P., McAinch A.J., Hatzinikolas G., Cameron-Smith D., Wittert G.A. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007, 267:63-69.
27. Esposito I., Proto M.C., Gazzerro P., Laezza C., Miele C., Alberobello A.T., et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008, 74:1678-1686.
28. Liu Y.L., Connoley I.P., Wilson C.A., Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005, 29:183-187.
29. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
30. Confavreux C.B., Levine R.L., Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009, 310:21-29.
31. Idris A.I., van 't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005, 11:774-779.
32. Tam J., Ofek O., Fride E., Ledent C., Gabet Y., Muller R., et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006, 70:786-792.
33. Tam J., Trembovler V., Di Marzo V., Petrosino S., Leo G., Alexandrovich A., et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008, 22:285-294.
34. Idris A.I., Sophocleous A., Landao-Bassonga E., Canals M., Milligan G., Baker D., et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009, 10:139-147.
35. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006, 103:696-701.
36. Idris A.I., Sophocleous A., Landao-Bassonga E., van't Hof R.J., Ralston S.H. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008, 149:5619-5626.
37. Rossi F., Siniscalco D., Luongo L., De Petrocellis L., Bellini G., Petrosino S., et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 2009, 44:476-484.
38. Scutt A., Williamson E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 2007, 80:50-59.
39. Bab I., Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 2008, 153:182-188.
40. Manolagas S.C., Jilka R.L., Kousteni S., Bellido T., Weinstein R.S., O'Brien C.A., et al. Response to Windahl et al. J Clin Invest 2006, 116:2834.
41. Karsak M., Cohen-Solal M., Freudenberg J., Ostertag A., Morieux C., Kornak U., et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005, 14:3389-3396.
42. Karsak M., Malkin I., Toliat M.R., Kubisch C., Nurnberg P., Zimmer A., et al. The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. Hum Genet 2009, 126:629-636.
43. Patel M.S., Elefteriou F. The new field of neuroskeletal biology. Calcif Tissue Int 2007, 80:337-347.
44. Melamed E., Robinson D., Halperin N., Wallach N., Keren O., Groswasser Z. Brain injury-related heterotopic bone formation: treatment strategy and results. Am J Phys Med Rehabil 2002, 81:670-674.
45. Boes M., Kain M., Kakar S., Nicholls F., Cullinane D., Gerstenfeld L., et al. Osteogenic effects of traumatic brain injury on experimental fracture-healing. J Bone Joint Surg Am 2006, 88:738-743.
46. Batetta B., Griinari M., Carta G., Murru E., Ligresti A., Cordeddu L., et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009, 139:1495-1501.
47. Matias I., Carta G., Murru E., Petrosino S., Banni S., Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008, 1781:52-60.
48. Artmann A., Petersen G., Hellgren L.I., Boberg J., Skonberg C., Nellemann C., et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008, 1781:200-212.
49. Berger A., Crozier G., Bisogno T., Cavaliere P., Innis S., Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 2001, 98:6402-6406.
50. Watanabe S., Doshi M., Hamazaki T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 2003, 69:51-59.
51. Watkins B.A., Li Y., Allen K.G.D., Hoffmann W.E., Seifert M.F. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr 2000, 130:2274-2284.
52. Watkins B.A., Li Y., Seifert M.F. Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats. J Nutr Biochem 2006, 17:282-289.
53. Watkins B.A., Lippman H.E., Le Bouteiller L., Li Y., Seifert M.F. Bioactive fatty acids: role in bone biology and bone cell function. Prog Lipid Res 2001, 40:125-148.
54. Watkins B.A., Li Y., Lippman H.E., Feng S. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot Essent Fatty Acids 2003, 68:387-398.
55. Fernandes G., Lawrence R., Sun D. Protective role of n-3 lipids and soy protein in osteoporosis. Prostaglandins Leukot Essent Fatty Acids 2003, 68:361-372.
56. Mori T.A., Beilin L.J. Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001, 12:11-17.
57. Raisz L.G., Alander C.B., Simmons H.A. Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture. Prostaglandins 1989, 37:615-625.
58. Ehrlich P.J., Lanyon L.E. Mechanical strain and bone cell function: a review. Osteoporos Int 2002, 13:688-700.
59. Frost H.M. On the pathogenesis of osteogenesis imperfecta: Some insights of the Utah paradigm of skeletal physiology. J Musculoskel Neuron Interact 2003, 3:1-7.
60. Judex S., Boyd S., Qin Y., Miller L., Müller R., Rubin C. Combining high-resolution micro-computed tomography with material composition to define the quality of bone tissue. Curr Osteoporos Rep 2003, 1:11-19.
61. Wohl G.R., Loehrke L., Watkins B.A., Zernicke R.F. Effects of high-fat diet on mature bone mineral content, structure, and mechanical properties. Calcif Tissue Int 1998, 63:74-79.
62. Reinwald S., Li Y., Moriguchi T., Salem N., Watkins B.A. Repletion with (n-3) fatty acids reverses bone structural deficits in (n-3)-deficient rats. J Nutr 2004, 134:388-394.
63. Schoenau E., Fricke O. Interaction between Muscle and Bone. Horm Res Paediatr 2006, 66:73-78.
64. Schoenau E., Frost H.M. The "muscle-bone unit" in children and adolescents. Calcif Tissue Int 2002, 70:405-407.
65. Ozdurak R.H., Duz S., Arsal G., Akinci Y., Kablan N., Isikli S., et al. Quantitative forearm muscle strength influences radial bone mineral density in osteoporotic and healthy males. Technol Health Care 2003, 11:253-261.
66. Ducher G., Jaffre C., Arlettaz A., Benhamou C.L., Courteix D. Effects of long-term tennis playing on the muscle-bone relationship in the dominant and nondominant forearms. Can J Appl Physiol 2005, 30:3-17.
67. Frost H.M. Bone's mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol 2003, 275:1081-1101.
68. Gray B., Hsu J.D., Furumasu J. Fractures caused by falling from a wheelchair in patients with neuromuscular disease. Dev Med Child Neurol 1992, 34:589-592.
69. Lingam S., Joester J. Spontaneous fractures in children and adolescents with cerebral palsy. Bmj 1994, 309:265.
70. El-Gammal T.A., El-Sayed A., Kotb M.M. Reconstruction of lower limb bone defects after sarcoma resection in children and adolescents using free vascularized fibular transfer. J Pediatr Orthop B 2003, 12:233-243.
71. Schoenau E. From mechanostat theory to development of the "functional muscle-bone-unit". J Musculoskelet Neuronal Interact 2005, 5:232-238.
72. Hamrick M.W., Pennington C., Byron C.D. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res 2003, 21:1025-1032.
73. Hamrick M.W. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol 2003, 272:388-391.
74. Hogstrom M., Nordstrom P. Nordstrom A. n-3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study. Am J Clin Nutr 2007, 85:803-807.
75. Kruger M.C., Coetzer H., de Winter R., Gericke G., van Papendorp D.H. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging 1998, 10:385-394.
76. Weiss L.A., Barrett-Connor E., von Muhlen D. Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am J Clin Nutr 2005, 81:934-938.
77. Watkins B.A., Reinwald S., Li Y., Seifert M.F. Protective actions of soy isoflavones and n-3 PUFA on bone mass in ovariectomized rats. J Nutr Biochem 2005, 16:479-488.
78. Bhattacharya A., Rahman M., Sun D., Fernandes G. Effect of fish oil on bone mineral density in aging C57BL/6 female mice. J Nutr Biochem 2007, 18:372-379.
79. Poulsen R.C., Firth E.C., Rogers C.W., Moughan P.J., Kruger M.C. Specific effects of gamma-linolenic, eicosapentaenoic, and docosahexaenoic ethyl esters on bone post-ovariectomy in rats. Calcif Tissue Int 2007, 81:459-471.
80. Li Y., Greiner R.S., Salem N., Watkins B.A. Impact of dietary n-3 FA deficiency on rat bone tissue FA composition. Lipids 2003, 38:683-686.
81. Coetzee M., Haag M., Kruger M.C. Effects of arachidonic acid and docosahexaenoic acid on differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cell Biochem Funct 2009, 27:3-11.
82. Bassey E.J., Littlewood J.J., Rothwell M.C., Pye D.W. Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone. Br J Nutr 2000, 83:629-635.
83. Poulsen R.C., Kruger M.C. Detrimental effect of eicosapentaenoic acid supplementation on bone following ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids 2006, 75:419-427.
84. Eriksson S., Mellstrom D., Strandvik B. Fatty acid pattern in serum is associated with bone mineralisation in healthy 8-year-old children. Br J Nutr 2009, 102:407-412.
85. Gronowitz E., Mellstrom D., Strandvik B. Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. Br J Nutr 2006, 95:1159-1165.
86. Eckardt K., Sell H., Taube A., Koenen M., Platzbecker B., Cramer A., et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009, 52:664-674.
87. Booth F.W., Thomason D.B. Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. Physiol Rev 1991, 71:541-585.
88. Hermansen L., Hultman E., Saltin B. Muscle glycogen during prolonged severe exercise. Acta Physiol Scand 1967, 71:129-139.
89. Booth F.W., Neufer D.P. Exercise controls gene expression. Am Sci 2005, 93:28-35.
90. Bonen A. PGC-1alpha-induced improvements in skeletal muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab 2009, 34:307-314.
91. Hawley J.A., Lessard S.J. Exercise training-induced improvements in insulin action. Acta Physiol (Oxf) 2008, 192:127-135.
92. Kraniou G.N., Cameron-Smith D., Hargreaves M. Acute exercise and GLUT4 expression in human skeletal muscle: influence of exercise intensity. J Appl Physiol 2006, 101:934-937.
93. Taouis M., Dagou C., Ster C., Durand G., Pinault M., Delarue J. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab 2002, 282:664-671.
94. Kawamura T., Yoshida K., Sugawara A., Nagasaka M., Mori N., Takeuchi K., et al. Regulation of skeletal muscle peroxisome proliferator-activated receptor gamma expression by exercise and angiotensin-converting enzyme inhibition in fructose-fed hypertensive rats. Hypertens Res 2004, 27:61-70.
95. Hevener A.L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 2003, 9:1491-1497.
96. Chambrier C., Bastard J.P., Rieusset J., Chevillotte E., Bonnefont-Rousselot D., Therond P., et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res 2002, 10:518-525.
97. Little J., Li Y., Watkins B.A., Hannon K. Dietary n-3 PUFA promote endurance training and fat loss in male mice. The FASEB Journal 2006, 20:A590-A591.